| Not Yet Recruiting | Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. NCT07402213 | Jemincare | Phase 3 |
| Recruiting | A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chr NCT07316114 | Sanofi | — |
| Recruiting | Remibrutinib in Real-world Clinical Practice NCT07358364 | Novartis Pharmaceuticals | — |
| Recruiting | Remibrutinib in Real-world Clinical Practice - a US Sub-study NCT07358780 | Novartis Pharmaceuticals | — |
| Recruiting | A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients NCT07408219 | Novartis Pharmaceuticals | — |
| Withdrawn | Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria NCT06795373 | Ahuva D Cices | Phase 2 |
| Recruiting | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous NCT07256392 | Celldex Therapeutics | Phase 3 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single an NCT07230418 | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 |
| Recruiting | A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. NCT07219615 | Pfizer | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Dos NCT07005713 | BeiGene | Phase 1 |
| Recruiting | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) NCT06931405 | Blueprint Medicines Corporation | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in NCT06864507 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) NCT06873516 | Evommune, Inc. | Phase 2 |
| Recruiting | A Study of Efficacy and Safety of TLL-018 in CSU Participants NCT06396026 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 3 |
| Active Not Recruiting | A Study of Single Dose of LP-003 in Healthy Adult Subjects NCT06604949 | Longbio Pharma | Phase 1 |
| Completed | Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Complet NCT06577116 | Allakos Inc. | Phase 1 |
| Recruiting | Trial of JYB1904 in Chronic Spontaneous Urticaria. NCT06509334 | Jemincare | Phase 2 |
| Active Not Recruiting | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) NCT06455202 | Celldex Therapeutics | Phase 3 |
| Active Not Recruiting | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria NCT06445023 | Celldex Therapeutics | Phase 3 |
| Recruiting | To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria NCT06365879 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Phase 3 |
| Active Not Recruiting | A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Ge NCT06991608 | Novartis Pharmaceuticals | — |
| Unknown | Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU) NCT06250400 | Hangzhou Grand Biologic Pharmaceutical, Inc. | Phase 4 |
| Completed | A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in NCT06053801 | Novartis Pharmaceuticals | — |
| Completed | Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment NCT06228560 | Longbio Pharma | Phase 2 |
| Recruiting | Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria NCT05916937 | Simon Francis Thomsen | Phase 4 |
| Unknown | A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria NCT06295302 | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. | Phase 2 |
| Unknown | Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy NCT04404023 | UBP Greater China (Shanghai) Co., Ltd | Phase 1 |
| Active Not Recruiting | Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquili NCT06162728 | Jasper Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With NCT06042478 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in S NCT06077773 | Escient Pharmaceuticals, Inc | Phase 2 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and NCT06072157 | Allakos Inc. | Phase 1 |
| Completed | A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases NCT05960708 | Yuhan Corporation | Phase 1 |
| Unknown | Assessment of Serum Levels of Adenosine Deaminase and Immunoglobulin E in Patients With Chronic Spontaneous Ur NCT05992987 | Sohag University | — |
| Completed | Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria NCT05936567 | Incyte Corporation | Phase 2 |
| Recruiting | 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adoles NCT05677451 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic S NCT05795153 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urtic NCT05513001 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria NCT05528861 | Allakos Inc. | Phase 2 |
| Unknown | A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an a NCT05298215 | United BioPharma | Phase 2 |
| Completed | A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of A NCT05526521 | Sanofi | Phase 3 |
| Withdrawn | A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria NCT05129423 | Genentech, Inc. | Phase 2 |
| Completed | A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants NCT06294288 | Longbio Pharma | Phase 1 |
| Completed | A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria NCT05335499 | Taiho Pharmaceutical Co., Ltd. | Phase 2 |
| Suspended | Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU) NCT06108869 | Royal College of Surgeons, Ireland | N/A |
| Completed | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria NCT05368285 | Celldex Therapeutics | Phase 2 |
| Completed | Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. NCT05373355 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Phase 1 |
| Unknown | STOP CSUA: phySical acTivity, mOod and sleeP in Chronic Spontaneous Urticaria and Angioedema NCT05169645 | St. James's Hospital, Ireland | — |
| Completed | A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled NCT05048342 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controll NCT05032157 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controll NCT05030311 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite th NCT05107115 | Sanofi | Phase 2 |
| Withdrawn | Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Re NCT04827589 | Gilead Sciences | Phase 2 |
| Unknown | Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refra NCT04944602 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria NCT04893980 | Second Xiangya Hospital of Central South University | Phase 2 / Phase 3 |
| Completed | Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria NCT04833855 | Amgen | Phase 2 |
| Completed | To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria NCT04426890 | Celltrion | Phase 3 |
| Terminated | A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptoma NCT04612725 | AstraZeneca | Phase 2 |
| Completed | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria NCT04538794 | Celldex Therapeutics | Phase 1 |
| Terminated | Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria NCT04513548 | Novartis Pharmaceuticals | Phase 1 |
| Terminated | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Partici NCT04444466 | UCB Biopharma SRL | Phase 1 |
| Terminated | Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous NCT04210843 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in C NCT04439955 | Stero Biotechs Ltd. | Phase 2 |
| Completed | Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Us NCT04180488 | Sanofi | Phase 3 |
| Unknown | Tranexamic Acid and Spontaneous Chronic Urticaria NCT03789422 | University Hospital, Grenoble | Phase 4 |
| Terminated | A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria NCT04159701 | Eli Lilly and Company | Phase 2 |
| Completed | An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU NCT04109313 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Mepolizumab for the Treatment of Chronic Spontaneous Urticaria NCT03494881 | Mayo Clinic | EARLY_Phase 1 |
| Completed | This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Cont NCT03926611 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Frequency of Parasite Infestation in Patients With Chronic Spontaneous Urticaria NCT04314999 | University Hospital, Basel, Switzerland | — |
| Completed | A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlle NCT03907878 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC NCT03661866 | Target PharmaSolutions, Inc. | — |
| Completed | Dupilumab in Chronic Spontaneous Urticaria NCT03749135 | Charite University, Berlin, Germany | Phase 2 |
| Completed | A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequatel NCT03580356 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inad NCT03580369 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticar NCT03437278 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Shotblocker® Use in Subcutaneous Injection NCT04210323 | Saglik Bilimleri Universitesi | N/A |
| Completed | Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria NCT03328897 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Pat NCT02649218 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU NCT02477332 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria NCT02372604 | Hospices Civils de Lyon | Phase 3 |
| Completed | Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatmen NCT02550106 | Novartis Pharmaceuticals | Phase 4 |
| Completed | OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticari NCT02161562 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to NCT01723072 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Pa NCT01803763 | Insel Gruppe AG, University Hospital Bern | Phase 2 / Phase 3 |
| No Longer Available | Global Managed Access Program Cohort for Ligelizumab in CSU NCT04903613 | Novartis Pharmaceuticals | — |
| Available | Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria NCT05170724 | Novartis Pharmaceuticals | — |